The Journal of Urology
Volume 181, Issue 4 , Pages 1628-1634 , April 2009

Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer

  • Simon L. Conti
    • ,
  • Marc Dall'Era
    • ,
  • Vincent Fradet

      Affiliations

    • Recipient of the McLaughlin Dean's grant, Laval University.
    • ,
  • Janet E. Cowan

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceutical Products, Inc.
    • ,
  • Jeffery Simko

      Affiliations

    • Financial interest and/or other relationship with BioImagene, Abbott Molecular, Genomic Health, Amgen and Genentech.
    • ,
  • Peter R. Carroll

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Urology, 1600 Divisadero St., Room A628, San Francisco, California 94143-1695 (telephone: 415-353-7098; FAX: 415-353-7093)
    • Financial interest and/or other relationship with TAP Pharmaceuticals, National Cancer Institute and AstraZeneca.

Received 18 August 2008

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14
  3. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146
  4. Draisma G, Boer R, Otto SJ, van derCruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868
  5. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors (A contemporary analysis). Cancer. 2004;101:2001
  6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368
  7. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664
  8. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359
  9. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956
  10. Loblaw DA, Choo R, Zhang L, Danjoux C, Morton GC, Holden L et al: Updated follow-up of active surveillance with selected delayed intervention for localized prostate cancer. Abstract 37, presented at ASCO Prostate Cancer Symposium, San Francisco, California, February 24–26, 2006.
  11. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520
  12. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th ed.. New York: Springer; 2002;
  13. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol. 2003;169:136
  14. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol. 2008;54:1306
  15. Cam K, Yucel S, Turkeri L, Akdas A. Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens. Int J Urol. 2002;9:257
  16. Bostwick DG. Gleason grading of prostatic needle biopsies (Correlation with grade in 316 matched prostatectomies). Am J Surg Pathol. 1994;18:796
  17. King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer. 2000;90:305
  18. Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001;32:74
  19. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005;97:1236

 Study received institutional review board approval.

 Supported by National Institutes of Health Prostate Cancer SPORE Grant 1P50CA089520-01.

 See Editorial on page 1534.

PII: S0022-5347(08)03270-9

doi: 10.1016/j.juro.2008.11.107

The Journal of Urology
Volume 181, Issue 4 , Pages 1628-1634 , April 2009

Article Tools